During the virtual 2021 Annual Congress of the European Society for Medical Oncology (ESMO), 16-21 September, research (co) led by VHIO investigators revealed promising advances in the treatment of metastatic breast cancer. ...
Sep 20, 2021
0
3
Thomas Hatschek, associate professor at the department of Oncology-Pathology, together with colleagues, has recently published an article in JAMA Oncology showing that a new treatment for breast cancer with an antibody linked ...
Aug 18, 2021
0
337
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results ...
Jun 29, 2020
0
2
A new study published in Oncotarget reports that despite relevant medical advancements, metastatic breast cancer remains an incurable disease.
Jun 04, 2020
0
1
Results of the NRG Oncology clinical trial RTOG 1010 indicate that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival (DFS) outcomes for patient ...
Jun 01, 2020
0
0
The addition of the monoclonal antibody therapy trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma ...
May 29, 2020
0
0
Anthracyclines remain a cornerstone of breast cancer therapy in combination with new-generation targeted drugs such as trastuzumab. Both types of drugs are major culprits in chemotherapy-induced heart disease. A recent study ...
Dec 23, 2019
0
2
The World Health Organization (WHO) announced Wednesday that it had for the first time approved a "biosimilar" medicine—one derived from living sources rather than chemicals—to make breast cancer treatment affordable ...
Dec 18, 2019
0
17
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast ...
Nov 22, 2019
0
2
Despite trastuzumab being a game-changing treatment for HER2-positive breast cancers over the past two decades, its success has come with key gaps in the understanding of how, exactly, it works.
Nov 15, 2019
0
7
